Key facts
- This page summarizes Syntone Ventures LLC's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Apr 2024, 20:21.
Syntone Ventures LLC - 15 Apr 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- OTLK
- Reported as of
- 15 Apr 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jiahui Zheng, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Syntone Ventures LLC filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 17 Apr 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OTLK
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +714,286
- Change %
- +72%
- Price
- Shares after
- 1,705,438
- Date
- 15 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OTLK
transaction
Derivative
Warrant (Right to Buy)
Purchase
- Transaction value
- Shares
- +1,071,429
- Change %
- Price
- Shares after
- 1,071,429
- Date
- 15 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,071,429
- Exercise price
- $7.70
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the "SPA"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the "Issuer") and Syntone Ventures LLC ("Syntone"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024.
Footnote F2
Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the "Reverse Stock Split"). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock.